CCG-1423 - CAS 285986-88-1
Catalog number:
285986-88-1
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C18H13ClF6N2O3
Molecular Weight:
454.75
COA:
Inquire
Targets:
Ras
Description:
CCG-1423 is a novel inhibitor of RhoA/C-mediated gene transcription that is capable of inhibiting invasion of PC-3 prostate cancer cells in a Matrigel model of metastasis.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
CCG-1423
MSDS:
Inquire
1.Stereospecific Inhibitory Effects of CCG-1423 on the Cellular Events Mediated by Myocardin-Related Transcription Factor A.
Watanabe B1, Minami S2, Ishida H3, Yoshioka R4, Nakagawa Y2, Morita T5, Hayashi K5. PLoS One. 2015 Aug 21;10(8):e0136242. doi: 10.1371/journal.pone.0136242. eCollection 2015.
CCG-1423 suppresses several pathological processes including cancer cell migration, tissue fibrosis, and the development of atherosclerotic lesions. These suppressions are caused by inhibition of myocardin-related transcription factor A (MRTF-A), which is a critical factor for epithelial-mesenchymal transition (EMT). CCG-1423 can therefore be a potent inhibitor for EMT. CCG-1423 and related compounds, CCG-100602 and CCG-203971 possess similar biological activities. Although these compounds are comprised of two stereoisomers, the differences in their biological activities remain to be assessed. To address this issue, we stereoselectively synthesized optically pure isomers of these compounds and validated their biological activities. The S-isomer of CCG-1423 rather than the R-isomer exhibited modestly but significantly higher inhibitory effects on the cellular events triggered by MRTF-A activation including serum response factor-mediated gene expression and cell migration of fibroblasts and B16F10 melanoma cells.
2.RPEL proteins are the molecular targets for CCG-1423, an inhibitor of Rho signaling.
Hayashi K1, Watanabe B2, Nakagawa Y3, Minami S3, Morita T1. PLoS One. 2014 Feb 18;9(2):e89016. doi: 10.1371/journal.pone.0089016. eCollection 2014.
Epithelial-msenchymal transition (EMT) is closely associated with cancer and tissue fibrosis. The nuclear accumulation of myocardin-related transcription factor A (MRTF-A/MAL/MKL1) plays a vital role in EMT. In various cells treated with CCG-1423, a novel inhibitor of Rho signaling, the nuclear accumulation of MRTF-A is inhibited. However, the molecular target of this inhibitor has not yet been identified. In this study, we investigated the mechanism of this effect of CCG-1423. The interaction between MRTF-A and importin α/β1 was inhibited by CCG-1423, but monomeric G-actin binding to MRTF-A was not inhibited. We coupled Sepharose with CCG-1423 (CCG-1423 Sepharose) to investigate this mechanism. A pull-down assay using CCG-1423 Sepharose revealed the direct binding of CCG-1423 to MRTF-A. Furthermore, we found that the N-terminal basic domain (NB) of MRTF-A, which acts as a functional nuclear localization signal (NLS) of MRTF-A, was the binding site for CCG-1423.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Ras Products


CAS 1629265-17-3 K-Ras G12C-IN-1

K-Ras G12C-IN-1
(CAS: 1629265-17-3)

K-Ras G12C-IN-1 is a novel and irreversible inhibitor of mutant K-ras G12C.

CAS 1637739-82-2 BQU57

BQU57
(CAS: 1637739-82-2)

BQU57, a derivative of RBC8, is a selective GTPase Ral inhibitor relative to the GTPases Ras and RhoA.

CAS 285986-88-1 CCG-1423

CCG-1423
(CAS: 285986-88-1)

CCG-1423 is a novel inhibitor of RhoA/C-mediated gene transcription that is capable of inhibiting invasion of PC-3 prostate cancer cells in a Matrigel model of ...

CAS 1835283-94-7 Pan-RAS-IN-1

Pan-RAS-IN-1
(CAS: 1835283-94-7)

Pan-RAS-IN-1 is a pan-Ras inhibitor and exhibits lethality in cells partially dependent on expression of Ras proteins.

CAS 436133-68-5 Kobe0065

Kobe0065
(CAS: 436133-68-5)

CAS 1469338-01-9 6H05

6H05
(CAS: 1469338-01-9)

6H05 is a selective inhibitor of oncogenic mutant K-Ras(G12C) without affecting wild-type K-Ras.

CAS 75629-57-1 Oncrasin-1

Oncrasin-1
(CAS: 75629-57-1)

Oncrasin-1 is a potent and effective anticancer inhibitor that kills various human lung cancer cells with K-Ras mutations at low or submicromolar concentrations...

CAS 162520-00-5 Salirasib

Salirasib
(CAS: 162520-00-5)

Salirasib is a salicylic acid derivative with potential antineoplastic activity. Salirasib dislodges all Ras isoforms from their membrane-anchoring sites, there...

CAS 1469337-95-8 K-Ras(G12C) inhibitor 12

K-Ras(G12C) inhibitor 12
(CAS: 1469337-95-8)

K-Ras(G12C) inhibitor 12 is an allosteric inhibitor of oncogenic K-Ras(G12C).

CAS 878978-76-8 ML-098

ML-098
(CAS: 878978-76-8)

ML-098, also called as CID-7345532, is an activator of the GTP-binding protein Rab7 (EC50 = 77.6 nM) with selectivity without disrupting related GTPases cdc42, ...

CAS 1629268-00-3 ARS-853

ARS-853
(CAS: 1629268-00-3)

ARS-853 is a selective, allele-specific inhibitor of KRAS, which blocks KRAS signaling and suppresses tumor growth (IC50= 2.5 μM).

CAS 454453-49-7 kobe2602

kobe2602
(CAS: 454453-49-7)

CASIN
(CAS: 425399-05-9)

CASIN is a selective GTPase Cdc42 inhibitor ( IC50=2 uM), reduces active levels of Cdc42 in aged hematopoietic stem cells.

CAS 2060530-16-5 MDK30165

MDK30165
(CAS: 2060530-16-5)

MDK30165, also known as K-Ras(G12C) Inhibitor 6, is an irreversible, allosteric inhibitor of the K-Ras(G12C) mutant that causes 100% modification of the protein...

CAS 1629267-75-9 K-Ras G12C-IN-2

K-Ras G12C-IN-2
(CAS: 1629267-75-9)

K-Ras G12C-IN-2 is a novel and irreversible inhibitor of mutant K-ras G12C.

CAS 1629268-19-4 K-Ras G12C-IN-3

K-Ras G12C-IN-3
(CAS: 1629268-19-4)

K-Ras G12C-IN-3 is a novel and irreversible inhibitor of mutant K-ras G12C.

Chemical Structure

CAS 285986-88-1 CCG-1423

Quick Inquiry

Verification code

Featured Items